Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.
about
Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNestin depletion induces melanoma matrix metalloproteinases and invasionDiagnostic Immunohistochemistry in Cutaneous Neoplasia: An UpdateMolecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance.Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro
P2860
Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Evaluation of stromal HGF immu ...... ma response to RAF inhibitors.
@ast
Evaluation of stromal HGF immu ...... ma response to RAF inhibitors.
@en
type
label
Evaluation of stromal HGF immu ...... ma response to RAF inhibitors.
@ast
Evaluation of stromal HGF immu ...... ma response to RAF inhibitors.
@en
prefLabel
Evaluation of stromal HGF immu ...... ma response to RAF inhibitors.
@ast
Evaluation of stromal HGF immu ...... ma response to RAF inhibitors.
@en
P2093
P2860
P50
P1433
P1476
Evaluation of stromal HGF immu ...... oma response to RAF inhibitors
@en
P2093
Cecilia Lezcano
Chung-Wei Lee
George F Murphy
John F Thompson
Martin C Mihm
P2860
P2888
P304
P356
10.1038/MODPATHOL.2013.226
P50
P577
2014-01-17T00:00:00Z
P5875
P6179
1000664370